Overview

Tirofiban for the Prevention of Early Neurological Deterioration After Intravenous Thrombolysis in Acute Ischemic Stroke

Status:
NOT_YET_RECRUITING

Trial end date:
2026-06-30

Target enrollment:

Participant gender:

Summary

A prospective, multicenter, randomized, controlled, open-label, blinded endpoint trial to evaluate the safety and efficacy of intravenous administration of tirofiban for preventing early neurological deterioration after intravenous thrombolysis in patients with acute ischemic stroke.

Phase:

PHASE2

Details

Lead Sponsor:

Capital Medical University

Treatments:

Tirofiban